REGULATORY CONSIDERATIONS OF BIOSIMILARS AND CLINICAL DILEMA OF THEIR USE
Biomedical products are complex molecules, produced by living cells. More accurately, they are molecules that are naturally produced in the human body, like hormones or growth factors, monoclonal antibodies, blood products, immunological medicinal products, sera and vaccines, allergens, and advanced...
Main Authors: | Sonja Genadieva Stavrik, Aleksandra Grozdanova, Katerina Ancevska Netkovska, Magdalena Genadieva Dimitrova, Gligor Dimitrov |
---|---|
Format: | Article |
Language: | English |
Published: |
Association of medical doctors Sanamed Novi Pazar
2017-04-01
|
Series: | Sanamed |
Subjects: | |
Online Access: | http://www.sanamed.rs/OJS/index.php/Sanamed/article/view/158/85 |
Similar Items
-
Quality, Non-clinical and Clinical Considerations for Biosimilar Monoclonal Antibody Development: EU, WHO, USA, Canada, and BRICS-TM Regulatory Guidelines
by: Hasumati Rahalkar, et al.
Published: (2018-09-01) -
Biosimilars for Haematologic Malignancies: The Path to Sustainable Care
by: Paul Cornes, et al.
Published: (2017-08-01) -
Comparative Safety Profiles of Oncology Biosimilars vs. Originators in Europe: An Analysis of the EudraVigilance Database
by: Victoria Nikitina, et al.
Published: (2023-07-01) -
Ten years of biosimilars in Europe: development and evolution of the regulatory pathways
by: Schiestl M, et al.
Published: (2017-05-01) -
A Regulatory Perspective on Biosimilar Medicines
by: Marta Agostinho Cordeiro, et al.
Published: (2024-02-01)